Abstract Irinotecan (CPT-11) has shown emerging promise in the treatment of malignant gliomas. It is believed the mechanism of action of irinotecan is to sensitize glioma cells to the cytotoxic action of radiation therapy and alkylating agents. However, clinical trials using weekly or three-weekly doses of CPT-11 have demonstrated imaging responses in only 10-15% of patients. In this study, we evaluated another mechanism of action, angiosuppression by CPT-11 of ACNU-resistant gliomas, using a metronomic administration schedule. Two different types of treatment, (1) conventional and (2) metronomic, were applied to the subcutaneous U87 model. We found that metronomic administration of CPT-11 significantly inhibited malignant glioma growth by inhibiting angiogenesis; this treatment procedure reduced the number of tumor vessels and the area of hypoxic lesions and reduced expression of VEGF and HIF-1a, the most important angiogenic factors in gliomas. Metronomic treatment was superior to conventional treatment with regard to the severe systemic side effect of body weight loss. The growth inhibitory effect was very similar for both low and high doses of CPT-11. These angiosuppressive effects of CPT-11 show promise for another use of CPT-11 in metronomic and scheduled angiosuppressive chemotherapy with low dose and long-term administration for malignant gliomas without systemic side effects.
Introduction
Malignant gliomas have remained a major cause of death in adults and children despite therapeutic strategies that include maximum surgical resection followed by radiochemotherapy. Although there is great promise for future strategies involving anti-angiogenic agents, chemotherapy, or vaccines, it is likely to be years before we see true therapeutic benefits from these newer modalities. Other than the nitrosoureas (BCNU, ACNU, CCNU) and temozolomide, no agents have consistently resulted in clinical benefits for patients with gliomas.
Irinotecan has shown emerging promise in the treatment of malignant gliomas following many laboratory studies and phase I and II clinical trials [1, 2] . Currently, a phase II trial of BCNU and CPT-11 in adults with newly diagnosed or recurrent malignant gliomas, and phase I and II trials of CPT-11 and temozolomide are ongoing. CPT-11 may be important to neuro-oncology for a number of reasons. CPT-11, a topoisomerase I inhibitor, utilizes a different mechanism of action compared with other glioma therapies, particularly the alkylating agents. Preclinical and clinical data indicate that irinotecan may sensitize glioma cells to the cytotoxic actions of radiation therapy and alkylating agents. In addition, CPT-11 is among a small group of cytotoxic agents that readily cross the blood-brain barrier. However, clinical trials using weekly or three-weekly doses of irinotecan have demonstrated imaging responses in only 10-15% of patients. Recent data for CPT-11 and bevacizumab combination therapy suggests there is a synergy between irinotecan and ant-VEGF therapies, with acceptable toxicity [3] . We have demonstrated the antiangiogenic action of CPT-11 in vitro [4] , including the anti-VEGF and anti-HIF (hypoxia inducible factor) effects of CPT-11 itself. Moreover, metronomic dosing regimenseither continuous infusion or frequent administration without extended rest periods-could be targeting proliferating endothelial cells in the tumor [5] . In this study, we evaluated another mechanism of action, angiosuppression, of CPT-11 using a metronomic schedule in vivo in the glioma model.
Materials and methods

Establishment of the ACNU-resistant clone: U87AR
Because U87-MG has been known to express low levels of O 6 -methylguanine-DNA methyltransferase (MGMT) mRNA, which is involved in the drug resistance of tumor cells to ACNU (Mineura et al., 1996) , we chose U87 MG for establishment of the ACNU-resistant clone. U87-MG was obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were maintained in MEM supplemented with 10% FCS in a humidified atmosphere containing 5% CO 2 at 37°C. U87 MG was cultured in MEM supplemented with 10% FCS and 10 lM ACNU in a humidified atmosphere containing 5% CO 2 at 37°C, and the medium was changed twice a week for five weeks. Total RNA was extracted from glioma cells using the RNeasy mini kit (Qiagen, Germany) and we performed RT-PCR using the GeneAmp RNA PCR Kit (Perkin-Elmer Cetus, Norwalk, CT, USA), as described previously [6] . Briefly, 1 lg total RNA was reverse transcribed by MuLV reverse transcriptase in the presence of random hexamers, followed by the indicated number of cycles of PCR reaction (95°C for 1 min, 55°C for 1 min, and 72°C for 1 min) in the presence of 2 lM MGMT-specific primers (35 cycles), or b-actin-specific primers (16 cycles) as a control. The MGMT primers included the reverse primer (5 0 -AT CCGATGCAGTGTTACACG-3 0 within exon 5) and the forward primer (5 0 -ACCGTTTGCGACTTGGTACT-3 0 within exon 1) [7] . The b-actin primers included the reverse primer (5 0 -GGAGTTGAAGGTAGTTTCGTG-3 0 ) spanning bases 2429-2409 and the forward primer (5 0 -CGGG AAATCGTGCGTGACAT-3 0 ) spanning bases 2107-2126 [8] . The predicted sizes of the amplified MGMT and b-actin DNA products were 923 and 214 bp, respectively. Quantification of these RT-PCR products was performed on a computer using the public domain NIH Image program (developed at the US National Institute of Health). After repeated exposure to ACNU, we obtained U87-MG cells that exhibited high expression of MGMT mRNA, which were referred to as U87AR.
U87-MG and U87AR glioma cell proliferation with chemotherapeutic agents (ACNU and SN38; active metabolite of CPT-11) was assessed using the MTT assays described previously [9] . ACNU was provided by Sankyo (Tokyo). SN38 was provided by Daiichi Pharmaceutical (Tokyo). MGMT expression was markedly enhanced in U87AR compared with U87-MG (data not shown). The calculated IC 50 with ACNU was 80 lM for U87-MG and 988 lM for U87AR. In contrast, the IC 50 with SN38 was 70 nM for U87-MG and 20 nM for U87AR. U87AR is ten times more resistant than U87-MG to ACNU. CPT-11 similarly inhibited both U87AR and U87-MG proliferation (data not shown).
U87AR SCID mouse subcutaneous model
After the implantation of 1 9 10 5 U87AR cells in the flank of six-week-old male SCID mice (Japan Clea, Japan), U87AR tumor tissue fragments were removed and then reimplanted into another SCID mouse flank. Harvested tumor fragments 1 mm 3 in size were simultaneously implanted into the flank of another SCID mouse. When the resulting tumors were palpable, the mice were allocated to each of the treatment groups. In the first set of studies, CPT-11 was administered to mice in a conventional schedule on days 11-15 and 18-22 via intraperitoneal (i.p.) injection at 10 (low dose) and 40 (high dose) mg/kg in 10% dimethylsulfoxide (DMSO) in 0.9% saline. The mice were divided into three groups (six per group), given CPT-11 low dose, CPT-11 high dose, or saline. Body weight and xenograft tumor dimensions were recorded every each day. In the second set of studies, CPT-11 was administered to the mice in a metronomic schedule on days 1-21 daily via i.p. injection at 1 (low dose) and 4 (high dose) mg/kg. The mice were divided into three groups (eight per group), and were treated with metronomic-CPT-11 low dose, metronomic-CPT-11 high dose, or saline. Body weight and xenograft tumor dimensions were recorded on each day. In the second experiment, 21 days after the implant, the tumor tissues were removed. In order to evaluate the hypoxic area in tumor sections, pimonidazole hydrochloride (Hypoxyprobe-1, Chemicon Temecula, CA, USA) was administered at 120 mg/kg just before sacrifice. A portion of the tissues was immediately fixed in 10% phosphate-buffered formalin for 48 h, paraffin embedded, and used for routine pathological diagnosis and immunohistochemistry. Other portions of the tissues were immediately frozen in liquid nitrogen and stored at -70°C. In the third set of studies, half of the animals treated by the metronomic schedule resumed the treatment after seven days cessation of treatment. The second cycle of metronomic administration occurred daily on days 29-50 via i.p. injection of CPT-11. The xenograft tumor dimensions were recorded every day. The protocols were in adherence with institutional guidelines for animal welfare and experimental conduct. CPT-11 was provided by Daiichi Pharmaceutical Company (Tokyo, Japan).
Antibodies and immunohistochemistry
The Dako LSAB kit for mouse and rabbit primary antibody (Dako, Glostrup, Denmark) was used [9] . Tissue sections were deparaffined and incubated with 10% normal goat serum in PBS for 20 min. The sections were then incubated with a polyclonal anti-VEGF antibody, A-20 (Santa Cruz Biotech, CA, USA) at a dilution of 1:100 (1 lg/ml IgG), a monoclonal MIB-1 antibody (Immunotech), and anti-HIF1a antibody (Chemicon) at a dilution of 1:100 in PBS overnight at 4°C, and a monoclonal anti-mouse CD31 antibody (BD Pharmingen) at a dilution of 1:50 (10 lg/ml) and anti-pimonidazole antibody (Chemicon) at a dilution of 1:20 in PBS for 60 min at room temperature. Chromatographically purified mouse IgG and rabbit IgG (Dako) at the same IgG concentration were used as negative controls. Sections were incubated with biotin-conjugated goat antimouse or anti-rabbit immunoglobulin for 10 min, followed by washing in PBS for 10 min. The sections were then incubated with peroxidase-conjugated streptavidin solution for 5 min, followed by washing in PBS for 5 min. Sections were then stained with freshly prepared aminoethylcarbazole solution for 10 min, followed by washing for 5 min in tap water. The sections were then counterstained with hematoxylin and mounted with aqueous mounting media. The intracellular VEGF immunostaining was assessed for tumor cells using a semiquantitative scale (-, not detected; ?, moderate; ??, strong). Nuclei positive for MIB-1 were determined by counting at least 1000 tumor cells in a homogeneously stained area.
Tumor vascular density
Vascular density was scored using the vasoproliferative component of the microscopic angiogenesis grading system (MAGS) that has been used to quantify angiogenesis in a variety of tumors [10] . The number of vessels in a 2009 field (0.31 mm 2 ) was measured in microvessel ''hot spots'' (i.e., microscopic areas containing the most dense collections of microvessels, identified initially under low power magnification) with the use of an Olympus microscope, AHBT3 (Olympus, Tokyo, Japan) on CD34-stained tissue sections. Vascular density was defined by averaging the number of vessels in the three most vascularized areas.
Measurement of VEGF and HIF-1a levels in tumor extracts
Tumor extracts were prepared by homogenizing the tumors in a buffer [10] . VEGF levels were measured in tumor extract supernatants by Quantikine human VEGF immunoassay (R&D systems, Minneapolis, MN, USA). VEGF levels were normalized to total extract protein concentration as measured by DC protein assay and expressed as pg VEGF/mg total extract protein.
Total RNA from frozen tumor samples was collected using the RNeasy mini kit (Qiagen, Maryland, MD, USA). Total RNA of 1 lg/ll or less was used to perform RT-PCR using the GeneAmp RNA PCR kit (Applied Biosystems, Foster, CA, USA). The RT-PCR conditions were: 30 s at 94°C, 30 s at 55°C, 30 s at 72°C. To visualize mRNA for human VEGF, HIF-1a and b-actin, RT-PCR was performed and the PCR products were visualized on agarose gels. The mRNA expression was then quantified by densitometry. The VEGF primers consisted of the reverse primer (5 0 -CC TGGTGAGAGATCTGGTTC-3 0 ) and the forward primer (5 0 -TCGGGCCTCCGAAACCATGA-3 0 ) [11] . The HIF-1a primers included the reverse primer (5 0 -CCCTGCAG TAGGTTTCTGCT-3 0 ) and the forward primer (5 0 -CTCA AAGTCGGACAGCCTCA-3 0 ) [12] .
Statistical analyses
Vascular density, MIB-1 positivities, tumor volumes, VEGF concentration, and densitometric measurements are expressed as the mean ± SD. Statistically significant differences between the groups were determined using oneway analysis of variance and Tukey's test. All P-values are two-sided; values were considered statistically significant for P \ 0.05.
Results
CPT-11 (conventional treatment) inhibits U87AR glioma growth but with systemic toxicity CPT-11 at low and high doses in conventional treatment significantly inhibited U87AR subcutaneous glioma growth more than 15 days after tumor implantation (Fig. 1a) . Median survival time for each treatment was 7.5 weeks (control), 10.6 weeks (CPT-11 low dose), and 11.5 weeks (CPT-11 high dose). The effect against growth inhibition was very similar between the low and high doses of CPT-11 treatments. However, the body weights of the mice treated with CPT-11 were significantly lower 18 days after treatment compared with control mice, suggesting that conventional CPT-11 treatment has systemic side effects even at a low doses.
CPT-11 (metronomic treatment) inhibits U87AR glioma growth without systemic toxicity Metronomic scheduling of CPT-11 inhibited U87AR glioma growth in a dose-dependent manner (Fig. 1b) . The total dose of CPT-11 administered was 21 and 84 mg/kg with the low dose and high dose metronomic schedules, respectively, i.e., one fifth of the dose with the conventional schedule. CPT-11 treatment significantly prolonged the survival of glioma-bearing mice (data not shown). The body weights of the mice treated with CPT-11 by the metronomic schedule were very similar to those of control mice, suggesting that metronomic CPT-11 treatment had no systemic side effects.
CPT-11 (metronomic schedule) inhibits U87AR angiogenesis and hypoxia
Metronomic CPT-11 treatment significantly reduced HIF1a mRNA expression (Fig. 2) . VEGF165 mRNA expression was lower than for controls, but was not significantly different. The U87AR proliferation rate was not different between the controls and the CPT-11 treatment groups (Fig. 3a) . However, the VEGF protein level was reduced in a dose-dependent manner after metronomic CPT-11 treatment (Fig. 3b) . Tumor angiogenesis was evaluated by vessel number and vessel area in the tissue sections. Metronomic CPT-11 treatment significantly reduced vessel number and area (Fig. 4) . Finally, HIF-1a expression and hypoxic area were evaluated by immunohistochemistry. In the control groups, HIF-1a expression was observed strongly in the tumor cells around the site of necrosis. Metronomic CPT-11 treatment resulted in reduced necrosis and reduced HIF-1a expression (Fig. 5a-c) . The hypoxic areas in tissue sections, which were positive for pimonidazole, were strongly observed around the necrosis in the control group. However, the pimonidazole-positive area was reduced in the metronomic CPT-11 treatment groups, at both low and high doses (Fig. 5d-f ).
CPT-11 (metronomic schedule) inhibition is cytostatic and exhibits resistance
Re-challenge of metronomic CPT-11 treatment occurred seven days after the discontinuation of treatment. The tumor started to grow rapidly after the discontinuation of the treatment. The inhibitory effect on tumor growth was minimized by re-challenge metronomic treatment (Fig. 6) . Body weight loss (-) Fig. 1 
Discussion
We have previously demonstrated that SN-38, an active metabolite of CPT-11, selectively inhibited endothelial cell proliferation and significantly reduced both HIF-1a and VEGF expression in glioma cells in a dose and timedependent manner [4] . The study clearly showed that CPT-11 had a direct anti-angiogenic effect on endothelial cells and indirectly on glioma cells via down-regulation of HIF1a and VEGF. In this study we demonstrated the effect of metronomic treatment with CPT-11 on glioma growth and angiogenesis. The most striking advantage of metronomic CPT-11 treatment compared with conventional high-dose intermittent usage of CPT-11 is that it has no systemic toxicity, such as loss of body weight. Another striking effect was inhibition of glioma angiogenesis by down-regulation of HIF-1a and VEGF, resulting in reduced vessel densities and areas in the treated groups. However, the limited effect of the re-challenge treatment suggests resistance to angiosuppression for solid tumors, including gliomas. Furthermore, CPT-11 had a dramatic growth-inhibitory effect in the ACNU-resistant glioma clone. Because ACNU and temozolomide are commonly used in Japan as alkylating agents for malignant gliomas [13] [14] [15] , the finding that CPT-11 is effective for the ACNU-resistant clone is clinically useful with regard to subsequent use of chemotherapy for recurrent cases. Antiangiogenic activity of metronomic CPT-11 treatment
Most anticancer drugs cause DNA damage and inhibit tumor cell proliferation. They are usually administered at high doses to kill as many tumor cells as possible. However, standard chemotherapeutic drugs, for example vincristine bleomycin, adriamycin, etoposide, 5-fluoruracil, carboplatin, paclitaxel, and cyclophosphamide, can target angiogenesis when the dose and frequency of administration are optimized. Among these chemotherapeutic agents, CPT-11 was more potent in inhibiting endothelial cell tube formation in vitro [4] . Therefore, we selected CPT-11 as a candidate metronomic agent for gliomas. The antiangiogenic properties of the camptothecins; 9-AC, topotecan, gimatecan, and CPT-11 have been c metronomic high dose). Hypoxic areas in tissue sections that were positive for pimonidazole were clearly observed around the necrosis in the control group (d). However, the pimonidazole-positive area was reduced in the metronomic CPT-11 treatment groups at both low (e) and high (f) dose demonstrated in both in-vitro and in-vivo assays [16] [17] [18] [19] [20] [21] [22] . Although the precise mechanism by which camptothecins affect angiogenesis remains unclear, these drugs may be valuable therapeutic agents for treatment of angiogenic tumors. Indeed, preclinical studies have indicated the ability of a number of established cytotoxic drugs, for example cyclophosphamide and vinblastine, to strongly inhibit the growth of sensitive and resistant tumors when administered according to an ''anti-angiogenic schedule'', i.e., continuous low-dose scheduling [23] [24] [25] , and many antitumor chemotherapeutic agents, including CPT-11, have been tested clinically for their antiangiogenic potential in systemic cancer [26] [27] [28] .
Continuous low-dose scheduling has been described as the most appropriate means of exploiting the antiangiogenic potential of cytotoxic drugs [5, 29] . Metronomic chemotherapy has been used experimentally [30] and applied clinically for glioblastoma. Tuettenberg et al. [31] demonstrated that metronomic temozolomide in combination with the COX-2 inhibitor rofecoxib was feasible, safe, and maintained a good quality of life for 13 patients with glioblastoma, especially those with tumors characterized by high angiogenic activity. Furthermore, Kong et al. [32] demonstrated that metronomic temozolomide treatment was effective for patients with recurrent temozolomide-refractory glioblastoma. We demonstrated that metronomic CPT-11 treatment reduced VEGF protein expression, which is the most potent and important angiogenic factor of gliomas and brain tumor stem cells [10, 33, 34] . HIF-1a mRNA expression was also strongly inhibited, even with low-dose metronomic CPT-11 treatment. In tissue sections, HIF-1a expression was reduced, and was associated with diminished necrosis and hypoxic areas detected by pimonidazole staining. The tumor cells within these hypoxic areas are likely to be important targets, because they are resistant to chemotherapy and radiation therapy. Anti-angiogenic treatment, for example metronomic CPT-11 treatment may overcome this problem, because of reduction of the hypoxic area. Metronomic CPT-11 treatment reduced the expression of VEGF protein. One suggested mechanism of CPT-11 inhibition of VEGF expression is down-regulation of HIF1a mRNA expression, i.e., directly upstream of the VEGF pathway [35] . Metronomic CPT-11 treatment reduced expression of VEGF protein, but not VEGF mRNA, in tumor tissues. The recently identified HIF-independent regulation of VEGF by the transcriptional coactivator PGC1a may be related to the down regulation of VEGF protein [36] . One important mechanism of the anti-tumoral effect of anti-angiogenesis agents is normalization of tumor vasculature, resulting in reduction of necrosis and of the hypoxic area in the tumor [37] . By contrast, overdose of antiangiogenic agents could result excessive vascular regression associated with increased necrosis and hypoxic area. The therapeutic window of anti-angiogenic agents including CPT-11 is narrow and the administration schedule and the dose of anti-angiogenic agents is very important.
The recent combination therapy with CPT-11 and the angiogenesis inhibitor, TNP470 and thrombospondin-1 shows promise in future developments for treatment of malignant gliomas as an alternative angiosuppressive treatment [38] . Moreover, dramatic recent advances in the treatment for malignant gliomas with bevacizumab (VEGF neutralizing antibody) combined with CPT-11 treatment [3] have suggested the usefulness of CPT-11 as an antiangiogenic, cytostatic agent, irrespective of its cytotoxic anti-tumor effect. Taken together, these results raise the possibility of the novel clinical application of CPT-11 to target hypoxia-inducible factor and VEGF.
Resistance to anti-angiogenesis treatment In our study, the growth-inhibitory effect of re-challenged metronomic CPT-11 treatment was limited. The lack of effectiveness on the re-growing phase is similar to that in a previous study [39] . There are three possible explanations of this finding:
1 the metronomic treatment is not effective for relatively large tumors, as demonstrated with other antiangiogenesis strategies; 2 the resistance to metronomic treatment appeared with the first treatment; or 3 the targeted tumor endothelial cells acquired resistance to CPT-11.
The timing of the anti-angiogenic treatment is important. Several clinical studies with metronomic chemotherapy have not been effective for recurrent glioblastomas. Metronomic chemotherapy with methotrexate and cyclophosphamide was ineffective in relapsed, heavily-pretreated glioblastoma [40] . Although there were some responders, oral metronomic regimens with four drugs, etoposide, cyclophosphamide, thalidomide, and celecoxib did not significantly improve overall survival in a heavily-pretreated group of malignant glioma patients who were generally ineligible for conventional protocols [41] . Although metronomic chemotherapy may not be useful in patients with advanced disease, further studies using more potent angiogenic agents in patients with less advanced disease may be warranted. The mechanisms of resistance include revascularization as a consequence of upregulation of alternative pro-angiogenic signals; protection of the tumor vasculature either by recruiting pro-angiogenic inflammatory cells or increased protective coverage by pericytes; and accentuated invasiveness of tumor cells into local tissues to co-opt the normal vasculature [42, 43] . Tumor endothelial cells are genetically distinct from normal endothelial cells. Tumor endothelial cell clones can acquire resistance to the chemotherapeutic agent used. To overcome resistance to antiangiogenesis treatment, the HIF regulatory network holds promise as a target, as with metronomic CPT-11 treatment, given its global effects on angiogenesis, invasion, and stress-adaptive cell physiology.
In summary, metronomic CPT-11 treatment inhibited human glioma growth in vivo even in the ACNU-resistant clone. Metronomic CPT-11 treatment had an anti-angiogenic effect, inhibited HIF-1a and VEGF expression, and reduced the area of the hypoxic lesion. Clinically, CPT-11 may be a useful chemotherapeutic agent especially for ACNU-treated, recurrent malignant gliomas, in part through its angiosuppressive effect. In combination with strategies that exhibit resistance to antiangiogenic treatment, metronomic CPT-11 treatment presents an exciting future opportunity for improving and sustaining the benefits of malignant glioma therapy.
